Premarket approval, usually shortened to PMA, is the US Food and Drug Administration's most stringent route for bringing many high-risk Class III medical devices to market. The manufacturer submits clinical and technical evidence showing reasonable assurance of safety and effectiveness for the device's specific intended use.
The review can include clinical results, device performance, manufacturing controls, labeling and the balance between expected benefits and risks. Unlike a smaller early feasibility study, a PMA submission is intended to support an actual marketing decision. Not every medical device uses this route; lower-risk devices may follow other regulatory pathways.
Approval is specific to the product, indication and conditions reviewed. It does not mean a device is risk-free, that it helps everyone with a related condition or that every later hardware and software change is automatically authorized. Manufacturers may have obligations to report problems and perform additional follow-up after approval.
For a brain-computer interface, distinguish permission to conduct a clinical trial, a Breakthrough Device designation, submission of a PMA and FDA approval of that PMA. These are different milestones. Medicare coverage and the price a patient pays are separate questions again.